
## Jacob T Borodovsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1011102/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Smoking, vaping, eating: Is legalization impacting the way people use cannabis?. International Journal of Drug Policy, 2016, 36, 141-147.	1.6	188
2	Emerging Trends in Cannabis Administration Among Adolescent Cannabis Users. Journal of Adolescent Health, 2019, 64, 487-493.	1.2	131
3	Online survey characterizing vaporizer use among cannabis users. Drug and Alcohol Dependence, 2016, 159, 227-233.	1.6	127
4	U.S. cannabis legalization and use of vaping and edible products among youth. Drug and Alcohol Dependence, 2017, 177, 299-306.	1.6	111
5	Emerging adult age status predicts poor buprenorphine treatment retention. Journal of Substance Abuse Treatment, 2014, 47, 202-212.	1.5	101
6	An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 73-86.	1.8	81
7	Benzodiazepine use during buprenorphine treatment for opioid dependence: Clinical and safety outcomes. Drug and Alcohol Dependence, 2013, 132, 580-586.	1.6	75
8	Technological Interventions for Medication Adherence in Adult Mental Health and Substance Use Disorders: A Systematic Review. JMIR Mental Health, 2019, 6, e12493.	1.7	72
9	A randomized controlled trial of buprenorphine taper duration among opioidâ€dependent adolescents and young adults. Addiction, 2016, 111, 1406-1415.	1.7	71
10	The potential impact of cannabis legalization on the development of cannabis use disorders. Preventive Medicine, 2017, 104, 31-36.	1.6	61
11	Technology-based Interventions for Preventing and Treating Substance Use Among Youth. Child and Adolescent Psychiatric Clinics of North America, 2016, 25, 755-768.	1.0	58
12	Association Between Benzodiazepine Use With or Without Opioid Use and All-Cause Mortality in the United States, 1999-2015. JAMA Network Open, 2020, 3, e2028557.	2.8	48
13	Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review. Journal of Addiction Medicine, 2018, 12, 170-183.	1.4	45
14	Studying Cannabis Use Behaviors With Facebook and Web Surveys: Methods and Insights. JMIR Public Health and Surveillance, 2018, 4, e48.	1.2	38
15	Clinician beliefs and attitudes about buprenorphine/naloxone diversion. American Journal on Addictions, 2013, 22, 574-580.	1.3	32
16	Legal cannabis laws, home cultivation, and use of edible cannabis products: A growing relationship?. International Journal of Drug Policy, 2017, 50, 102-110.	1.6	32
17	The Impact of a Family-Based Economic Intervention on the Mental Health of HIV-Infected Adolescents in Uganda: Results From SuubiÂ+ Adherence. Journal of Adolescent Health, 2021, 68, 742-749.	1.2	32
18	MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study. Addiction Science & Clinical Practice, 2018, 13, 21.	1.2	29

JACOB T BORODOVSKY

#	Article	IF	CITATIONS
19	Cannabis regulatory science: risk–benefit considerations for mental disorders. International Review of Psychiatry, 2018, 30, 183-202.	1.4	29
20	Perceived safety of cannabis intoxication predicts frequency of driving while intoxicated. Preventive Medicine, 2020, 131, 105956.	1.6	28
21	Exploring How Social Media Exposure and Interactions Are Associated With ENDS and Tobacco Use in Adolescents From the PATH Study. Nicotine and Tobacco Research, 2021, 23, 487-494.	1.4	25
22	Association Between Benzodiazepine or Z-Drug Prescriptions and Drug-Related Poisonings Among Patients Receiving Buprenorphine Maintenance: A Case-Crossover Analysis. American Journal of Psychiatry, 2021, 178, 651-659.	4.0	23
23	Greater delay discounting and cannabis coping motives are associated with more frequent cannabis use in a large sample of adult cannabis users. Drug and Alcohol Dependence, 2020, 207, 107820.	1.6	21
24	Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone. Scientific Reports, 2020, 10, 5617.	1.6	21
25	Use of highly-potent cannabis concentrate products: More common in U.S. states with recreational or medical cannabis laws. Drug and Alcohol Dependence, 2021, 229, 109159.	1.6	21
26	Web-Based Prescription Opioid Abuse Prevention for Adolescents: Program Development and Formative Evaluation. JMIR Formative Research, 2019, 3, e12389.	0.7	20
27	Delta-8 THC use in US adults: Sociodemographic characteristics and correlates. Addictive Behaviors, 2022, 133, 107374.	1.7	17
28	Age disparities in six-month treatment retention for opioid use disorder. Drug and Alcohol Dependence, 2020, 213, 108130.	1.6	16
29	A Decline in Propensity Toward Risk Behaviors Among U.S. Adolescents. Journal of Adolescent Health, 2019, 65, 745-751.	1.2	15
30	Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events. JAMA Network Open, 2021, 4, e210061.	2.8	13
31	U.S. Trends in Adolescent Substance Use and Conduct Problems and Their Relation to Trends in Unstructured In-Person Socializing With Peers. Journal of Adolescent Health, 2021, 69, 432-439.	1.2	12
32	Investigating the role of familial and peerâ€related factors on electronic nicotine delivery systems (ENDS) use among U.S. adolescents. Journal of Adolescence, 2021, 87, 98-105.	1.2	9
33	The importance of psychology for shaping legal cannabis regulation Experimental and Clinical Psychopharmacology, 2021, 29, 99-115.	1.3	9
34	National Trends of Adolescent Exposure to Tobacco Advertisements: 2012–2020. Pediatrics, 2021, 148, .	1.0	9
35	Technological Innovations in Addiction Treatment. , 2019, , 75-90.		8
36	Evaluating the Effectiveness of a Web-Based Program (POP4Teens) to Prevent Prescription Opioid Misuse Among Adolescents: Randomized Controlled Trial. JMIR Public Health and Surveillance, 2021, 7, e18487.	1.2	8

JACOB T BORODOVSKY

#	Article	IF	CITATIONS
37	Use patterns, beliefs, experiences, and behavioral economic demand of indica and sativa cannabis: A cross-sectional survey of cannabis users Experimental and Clinical Psychopharmacology, 2022, 30, 575-583.	1.3	8
38	Prevalence of Kratom Use and Co-Occurring Substance Use Disorders in the United States. primary care companion for CNS disorders, The, 2021, 23, .	0.2	8
39	Workshop on the Development and Evaluation of Digital Therapeutics for Health Behavior Change: Science, Methods, and Projects. JMIR Mental Health, 2020, 7, e16751.	1.7	8
40	Changes in associations between prescription opioid use disorder and illegal behaviors among adults in the United States from 2002 to 2014. Addiction, 2019, 114, 2150-2159.	1.7	6
41	Sifting through the weeds: Relationships between cannabis use frequency measures and delay discounting. Addictive Behaviors, 2021, 112, 106573.	1.7	6
42	The impact of discomfort with HIV status and hopelessness on depressive symptoms among adolescents living with HIV in Uganda. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 33, 867-872.	0.6	5
43	Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints Psychology of Addictive Behaviors, 2022, 36, 515-525.	1.4	5
44	Understanding Brain Damage and Sleep Apnea: A Review. Health Outcomes Research in Medicine, 2010, 1, e103-e110.	0.6	4
45	Trends in Prescribed Central Nervous System Depressant Medications Among Adults Who Regularly Consume Alcohol: United States 1999 to 2014. Alcoholism: Clinical and Experimental Research, 2019, 43, 1510-1518.	1.4	4
46	Co-occurring Disordered Gambling Among Treatment-Seekers at a Community Outpatient Addiction Clinic. Journal of Addiction Medicine, 2016, 10, 339-343.	1.4	3
47	The changing landscape of alcohol use disorder and problem drinking in the USA: implications for primary care. Family Practice, 2020, 37, 870-872.	0.8	3
48	An analysis of within-subject and population level risk related to substance use and mental health outcomes among adolescents in the PATH study. Drug and Alcohol Dependence, 2021, 218, 108385.	1.6	3
49	Cannabis vaping and health: regulatory considerations. Addiction, 2020, 115, 587-588.	1.7	2
50	Assessing the feasibility, usability and acceptability of the MySafeRx platform among individuals in outpatient buprenorphine treatment: Lessons learned from a pilot randomized controlled trial. , 2022, 3, 100045.		1
51	Important Questions About the Impact of Medical Marijuana on People With Serious Mental Illness. Psychiatric Services, 2018, 69, 1181-1183.	1.1	0
52	Commentary on Hamilton et al . (2019): Why aren't cannabis use rates declining among US adolescents?. Addiction, 2019, 114, 1773-1774.	1.7	0
53	Clinical Manifestations of Cannabis Use Disorder. , 2019, , 85-91.		0
54	Leveraging social media to rapidly recruit a sample of young adults aging out of foster care: Methods and recommendations. Children and Youth Services Review, 2020, 113, 104960.	1.0	0